Use of attenuated paramyxoviruses for cancer therapy
/in International Publications, Newcastle Disease VirusOptimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus[WT1 peptide pulsed dendritic cell therapy with activated T lymphocytes therapy for advanced cancers]
/in Dendritic Cells, Esophageal Carcinoma, International PublicationsPalliation of recurrent myxofibrosarcoma with radiotherapy and hyperthermia
/in Hyperthermia, International Publications, Soft Tissue SarcomaVaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
/in Dendritic Cells, International Publications, Multiple MyelomaVaccination with dendritic cells charged with apoptotic/necrotic B16 melanoma induces the formation of subcutaneous lymphoid tissue
/in Dendritic Cells, International PublicationsChemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International PublicationsResistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival
/in Dendritic Cells, International Publications, Malignant Melanoma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer